問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Ophthalmology

更新時間:2023-09-19

林伯剛
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

14Cases

2020-05-01 - 2021-08-20

Phase III

To determine if treatment with aflibercept 8 mg (HD) at intervals of 12 or 16 weeks provides non-inferior BCVA change compared to aflibercept 2 mg every 8 weeks in participants with nAMD
  • Condition/Disease

    NAMD

  • Test Drug

    BAY 86-5321

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2021-08-15 - 2024-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-01-07 - 2023-06-08

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2011-04-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 2